Overview

A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)

Status:
Not yet recruiting
Trial end date:
2026-12-16
Target enrollment:
Participant gender:
Summary
The purpose of this research is to evaluate the efficacy and the safety of two doses of ZSP1601 for 48 weeks versus placebo in adult NASH patients.
Phase:
Phase 2
Details
Lead Sponsor:
Guangdong Raynovent Biotech Co., Ltd